Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Neoplasia (New York, N.Y.)|October 9, 2017
Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by <sup>19</sup>F-MRI and Multispectral AnalysisYunzhou Shi, Jason Oeh, Anna Hitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2012
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivoJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 28, 2018
Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitorBianca M Liederer, Jonathan Cheong, Kang-Jye Chou, et al.
Neoplasia (New York, N.Y.)|September 15, 2019
VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical ModelsJohannes Riegler, Herman Gill, Annie Ogasawara, et al.
Science Signaling|April 18, 2013
Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinasesGuanglei Zhuang, Kebing Yu, Zhaoshi Jiang, et al.
Molecular Cancer Therapeutics|April 10, 2019
Neutralization of BCL-2/X<sub>L</sub> Enhances the Cytotoxicity of T-DM1 <i>In Vivo</i>Jason J Zoeller, Aleksandr Vagodny, Krishan Taneja, et al.
Nature Communications|August 30, 2017
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug responseIoannis K Zervantonakis, Claudia Iavarone, Hsing-Yu Chen, et al.
Molecular Cancer Therapeutics|March 12, 2013
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor modelsNguyen Tan, Maureen Wong, Michelle A Nannini, et al.
Neoplasia (New York, N.Y.)|December 17, 2013
Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysisYunzhou Shi, Jason Oeh, Jeffrey Eastham-Anderson, et al.
Haematologica|May 17, 2020
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsRaghuveer Singh Mali, Qi Zhang, Rosa Anna DeFilippis, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Neoplasia (New York, N.Y.)|October 9, 2017
Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by <sup>19</sup>F-MRI and Multispectral AnalysisYunzhou Shi, Jason Oeh, Anna Hitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2012
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivoJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 28, 2018
Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitorBianca M Liederer, Jonathan Cheong, Kang-Jye Chou, et al.
Neoplasia (New York, N.Y.)|September 15, 2019
VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical ModelsJohannes Riegler, Herman Gill, Annie Ogasawara, et al.
Science Signaling|April 18, 2013
Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinasesGuanglei Zhuang, Kebing Yu, Zhaoshi Jiang, et al.
Molecular Cancer Therapeutics|April 10, 2019
Neutralization of BCL-2/X<sub>L</sub> Enhances the Cytotoxicity of T-DM1 <i>In Vivo</i>Jason J Zoeller, Aleksandr Vagodny, Krishan Taneja, et al.
Nature Communications|August 30, 2017
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug responseIoannis K Zervantonakis, Claudia Iavarone, Hsing-Yu Chen, et al.
Molecular Cancer Therapeutics|March 12, 2013
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor modelsNguyen Tan, Maureen Wong, Michelle A Nannini, et al.
Neoplasia (New York, N.Y.)|December 17, 2013
Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysisYunzhou Shi, Jason Oeh, Jeffrey Eastham-Anderson, et al.
Haematologica|May 17, 2020
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsRaghuveer Singh Mali, Qi Zhang, Rosa Anna DeFilippis, et al.
Pageof 10